

Chordate Medical Holding AB (publ) Appoints Lago Kapital as Liquidity Provider for the Company's Preferred Share

Chordate Medical Holding AB (publ) ("Chordate" or the "Company") has entered into a liquidity provider agreement for the Company's preferred share with Lago Kapital ("Lago").

Under the agreement, Lago will place bid and ask orders in Chordate's preferred share in accordance with and within the framework of Nasdaq Stockholm's regulations for liquidity provision. The purpose of the liquidity provider arrangement is to improve liquidity and reduce volatility. Lago's assignment will commence on March 17, 2025.

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[Chordate Medical Holding AB \(publ\) Appoints Lago Kapital as Liquidity Provider for the Company's Preferred Share](#)